Oncorus to Present Initial Data from its Ongoing Phase 1 Clinical Trial of ONCR-177 at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
October 01 2021 - 8:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced it will present initial data from its
ongoing Phase 1 clinical trial of ONCR-177 at the upcoming Society
for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking
place November 12–14, 2021 in Washington, D.C. and virtually.
ONCR-177, Oncorus’ lead oncolytic Herpes Simplex Virus (oHSV)
product candidate, is an intratumorally (iTu) administered viral
immunotherapy being developed for multiple solid tumor indications.
The Phase 1 open-label, multi-center, dose escalation and expansion
clinical trial is designed to evaluate the safety and tolerability
of ONCR-177 alone and in combination with Merck’s anti-PD-1
therapy, KEYTRUDA® (pembrolizumab), in patients with advanced
and/or refractory cutaneous, subcutaneous or metastatic nodal solid
tumors or with liver metastases of solid tumors.
The details for Oncorus’ SITC poster are as follows:
Title: Initial results of a Phase 1 study of
intratumoral ONCR-177, an oncolytic herpes-simplex virus-1
expressing five immunomodulatory transgenes, in subjects with
advanced injectable tumorsAbstract #:
511Primary Author/Presenter: Jong Chul
Park, M.D., Instructor, Medicine, Harvard Medical School and
Assistant, Medicine, Massachusetts General Hospital
Date/Time: November 12–14, 2021, 7:00 a.m.– 8:30
p.m. ETLocation: Poster Hall, Walter
E. Washington Convention Center, Washington, D.C.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic viral
RNA (vRNA) Immunotherapy Platform.
Designed to deliver next-generation viral immunotherapy impact,
our oHSV Platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead oHSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering Synthetic vRNA Immunotherapy Platform involves a highly
innovative, novel combination of RNA- and oncolytic virus-based
modalities designed to realize the potential of RNA medicines for
cancer. Our lead IV-administered Synthetic vRNA Immunotherapy
clinical candidates, ONCR-021 and ONCR-788, are both currently in
IND-enabling studies.
Please visit www.oncorus.com to learn more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding the clinical development of ONCR-177,
including expectations regarding timing for reporting data from the
ongoing Phase 1 clinical trial, as well as the product candidate’s
therapeutic potential and clinical benefits and the utility and
potential of Oncorus’ oHSV Platform. The words "may," “might,”
"will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," “expect,” "estimate," “seek,” "predict,"
“future,” "project," "potential," "continue," "target" and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with: the impact of COVID-19 on
Oncorus’ operations and the timing and anticipated results of its
ongoing and planned clinical trials; the risk that the results of
preclinical studies and clinical trials may not be predictive of
future results in connection with future clinical trials; Oncorus’
ability to successfully demonstrate the safety, tolerability and
efficacy of ONCR-177, ONCR-021 and ONCR-788 and obtain regulatory
approval thereof; Oncorus’ ability to obtain the requisite
components for its product candidates manufactured in accordance
with regulatory requirements; the expansion of Oncorus’ in-house
manufacturing capabilities; the adequacy of Oncorus’ cash resources
and availability of financing on commercially reasonable terms; and
Oncorus’ ability to obtain, maintain and protect its intellectual
property. These and other risks and uncertainties are described in
greater detail in the section entitled "Risk Factors" in Oncorus’
Annual Report on Form 10-K for the year ended December 31,
2020, filed with the Securities and Exchange
Commission on March 10, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in the
other filings that Oncorus makes with the Securities
and Exchange Commission from time to time. These documents are
available under the “SEC filings” page of the Investors section of
Oncorus’ website at http://investors.oncorus.com. Any
forward-looking statements represent Oncorus’ views only as of the
date of this press release and should not be relied upon as
representing its views as of any subsequent
date. Oncorus explicitly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Media
Contact: Liz
Meloneliz@scientpr.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024